MCID: ENC004
MIFTS: 66

Encephalitis

Categories: Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Encephalitis

Summaries for Encephalitis

NINDS : 54 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Encephalitis is related to tick-borne encephalitis and herpes simplex encephalitis, and has symptoms including seizures, tremor and back pain. An important gene associated with Encephalitis is UNC93B1 (Unc-93 Homolog B1, TLR Signaling Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Azithromycin and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms.

MedlinePlus : 43 Encephalitis is an inflammation of the brain. Usually the cause is a viral infection, but bacteria can also cause it. It can be mild or severe. Most cases are mild. You may have flu-like symptoms. With a mild case, you may just need rest, plenty of fluids, and a pain reliever. Severe cases need immediate treatment. Symptoms of severe cases include Severe headache Sudden fever Drowsiness Vomiting Confusion Seizures In babies, additional symptoms may include constant crying, poor feeding, body stiffness, and bulging in the soft spots of the skull. Severe cases may require a stay in the hospital. Treatments include oral and intravenous (IV) medicines to reduce inflammation and treat infection. Patients with breathing difficulties may need artificial respiration. Some people may need physical, speech, and occupational therapy once the illness is under control. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Encephalitis is inflammation of the brain. Severity is variable. Symptoms may include headache, fever,... more...

Related Diseases for Encephalitis

Diseases in the Encephalitis family:

Viral Encephalitis Autoimmune Encephalitis

Diseases related to Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 737)
# Related Disease Score Top Affiliating Genes
1 tick-borne encephalitis 34.2 CCR5 CD209 CXCL10 TLR3
2 herpes simplex encephalitis 34.0 IRF3 TICAM1 TLR3 TRAF3 UNC93B1
3 japanese encephalitis 33.8 CCL5 CD209 CLEC4G CLEC4M CXCL10 DDX58
4 viral encephalitis 33.7 CCL2 CCL5 CXCL10 IL1B
5 west nile virus 32.6 CCR5 CD209 CLEC4M DDX58 IRF3 RSAD2
6 malaria 31.6 CCL2 CCL5 CXCL10 CXCL9 IL1B
7 herpes simplex 31.5 CD209 DDX58 IRF3 TICAM1 TLR3 TRAF3
8 dengue virus 30.7 CD209 DDX58 RPSA RSAD2
9 viral infectious disease 30.7 CCL5 CCR5 CD209 CXCL10 DDX58 IL1B
10 measles 30.6 CD209 DDX58 TLR3
11 rabies 30.6 CCL5 CXCL10 IRF3 TLR3
12 influenza 30.4 CCL5 CXCL10 DDX58 IRF3 RSAD2 TLR3
13 mouth disease 30.4 IL1B IRF3 TLR3
14 yellow fever 30.3 CCL2 CCL5 CCR5 RSAD2
15 viral meningitis 30.3 CCL2 CCL5 CXCL10
16 chikungunya 30.2 CCL2 CCL5 DDX58 IL1B RSAD2
17 pneumonia 30.2 CCL2 CCL5 IL1B
18 stomatitis 30.2 DDX58 IL1B RSAD2
19 opsoclonus-myoclonus syndrome 30.1 CXCL10 CXCL9
20 neuritis 30.0 AQP4 CCL2 CCL5 CXCL10 IL1B
21 trypanosomiasis 30.0 CCL2 CCL5 IL1B
22 lymphadenitis 29.9 CD209 CXCL9 IL1B
23 cerebral hemorrhage 29.9 GFAP IL1B
24 noonan syndrome 3 29.8 DDX58 IRF3 RSAD2 TLR3
25 systemic lupus erythematosus 29.7 CCL2 CCL5 CCR5 CXCL10 IL1B TLR3
26 demyelinating disease 29.7 AQP4 CCL2 CCL5 CXCL10 IL1B
27 cytomegalovirus infection 29.6 CCL2 CCL5 IL1B
28 hepatitis c 29.6 CLEC4M CXCL10 DDX58 IRF3 TLR3
29 human immunodeficiency virus type 1 29.5 CCL2 CCL5 CCR5 CD209 CLEC4M CXCL10
30 multiple sclerosis 29.5 AQP4 CCL2 CCL5 CCR5 CXCL10 CXCL9
31 hepatitis c virus 29.5 CCR5 CLEC4M DDX58 IRF3 RSAD2
32 pulmonary sarcoidosis 29.4 CCL2 CCL5 CCR5
33 severe acute respiratory syndrome 29.2 CCL2 CCL5 CD209 CLEC4M CXCL10 IRF3
34 nervous system disease 29.1 AQP4 CCL2 GFAP IL1B
35 central nervous system disease 28.9 AQP4 CCL2 CCR5 GFAP IL1B
36 la crosse encephalitis 12.6
37 st. louis encephalitis 12.6
38 eastern equine encephalitis 12.6
39 limbic encephalitis 12.5
40 rasmussen encephalitis 12.5
41 western equine encephalitis 12.5
42 murray valley encephalitis 12.4
43 granulomatous amebic encephalitis 12.4
44 autoimmune encephalitis 12.4
45 west nile encephalitis 12.4
46 venezuelan equine encephalitis 12.4
47 powassan encephalitis 12.4
48 limbic encephalitis with lgi1 antibodies 12.4
49 hhv-6 encephalitis 12.4
50 meningitis and encephalitis 12.4

Graphical network of the top 20 diseases related to Encephalitis:



Diseases related to Encephalitis

Symptoms & Phenotypes for Encephalitis

UMLS symptoms related to Encephalitis:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Encephalitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.12 RPSA
2 Decreased viability GR00221-A-1 10.12 CCL2
3 Decreased viability GR00221-A-4 10.12 CCL2
4 Decreased viability GR00231-A 10.12 CXCL10
5 Decreased viability GR00240-S-1 10.12 RPSA
6 Decreased viability GR00342-S-1 10.12 TLR3
7 Decreased viability GR00342-S-2 10.12 TLR3
8 Decreased viability GR00381-A-1 10.12 GFAP RPSA
9 Decreased viability GR00402-S-2 10.12 AQP4 CCL2 CCL5 CCR5 CD209 CLEC4G
10 no effect GR00402-S-1 9.62 AQP4 CCL2 CCL5 CCR5 CD209 CLEC4G

MGI Mouse Phenotypes related to Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 AQP4 CCL5 CCR5 CLEC4G CLEC4M CXCL10
2 homeostasis/metabolism MP:0005376 10 AQP4 CCR5 CLEC4G CLEC4M CXCL10 DDX58
3 immune system MP:0005387 9.86 AQP4 CCL2 CCL5 CCR5 CLEC4G CLEC4M
4 mortality/aging MP:0010768 9.44 AQP4 CCR5 CLEC4M CXCL10 DDX58 GFAP

Drugs & Therapeutics for Encephalitis

Drugs for Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 1 83905-01-5 55185 447043
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
4
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
5
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 68-35-9 5215
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 58-14-0 4993
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Formaldehyde Approved, Vet_approved Phase 4,Phase 3 50-00-0 712
9
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
10
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
11
Dimenhydrinate Approved Phase 4 523-87-5 441281
12
Emtricitabine Approved, Investigational Phase 4,Phase 2 143491-57-0 60877
13
Natalizumab Approved, Investigational Phase 4 189261-10-7
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
17
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
18
Racepinephrine Approved Phase 4 329-65-7 838
19
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
20
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
21 Dolutegravir Approved Phase 4 1051375-16-6 54726191
22
Cobicistat Approved Phase 4 1004316-88-4
23
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
25
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4 3871
26
Tenofovir Experimental, Investigational Phase 4,Phase 2 147127-20-6 464205
27
Prednisolone hemisuccinate Experimental Phase 4,Phase 2 2920-86-7
28 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Hematinics Phase 4
33 Epoetin alfa Phase 4 113427-24-0
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
37 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-HIV Agents Phase 4,Phase 1,Phase 2,Not Applicable
43 Anti-Retroviral Agents Phase 4,Phase 1,Phase 2,Not Applicable
44 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antibodies, Blocking Phase 4,Phase 3,Phase 2
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
47 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
49 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 331)
# Name Status NCT ID Phase Drugs
1 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
2 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
3 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
4 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Completed NCT02526550 Phase 4
5 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
6 Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Completed NCT02532569 Phase 4
7 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
8 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
9 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
10 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis Completed NCT02039440 Phase 4
11 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
12 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
13 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
14 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Completed NCT00894686 Phase 4
15 Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
16 Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine Completed NCT01398540 Phase 4
17 This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
18 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
19 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4 TicoVac
20 Treatment of Cerebral Toxoplasmosis in HIV/AIDS Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
21 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
22 Post-licensure Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
23 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
24 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
25 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
26 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
27 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
28 Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults Completed NCT00387634 Phase 4
29 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
30 Immunogenicity of SA 14-14-2 JE Vaccine Completed NCT01635816 Phase 4
31 Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years Completed NCT00452621 Phase 4
32 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
33 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
34 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® Completed NCT02511587 Phase 4
35 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events Completed NCT01417949 Phase 4
36 Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults Completed NCT02062281 Phase 4
37 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4 Minocycline
38 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
39 TBE Vaccination in Allergic Patients Completed NCT02511535 Phase 4
40 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
41 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
42 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
43 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
44 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Active, not recruiting NCT03294135 Phase 4
45 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4 teriflunomide
46 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
47 IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis Terminated NCT00774631 Phase 4
48 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated NCT01211665 Phase 4 Methylprednisolone;Prednisolone
49 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Withdrawn NCT03192371 Phase 4
50 Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis Unknown status NCT00545493 Phase 2, Phase 3 Tacrolimus;i.v. immunoglobulins

Search NIH Clinical Center for Encephalitis

Cochrane evidence based reviews: encephalitis

Genetic Tests for Encephalitis

Genetic tests related to Encephalitis:

# Genetic test Affiliating Genes
1 Encephalitis 29

Anatomical Context for Encephalitis

MalaCards organs/tissues related to Encephalitis:

41
Brain, T Cells, Testes, Lung, Spinal Cord, Temporal Lobe, B Cells

Publications for Encephalitis

Articles related to Encephalitis:

(show top 50) (show all 8372)
# Title Authors Year
1
Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein. ( 30455470 )
2019
2
Emergence of tick-borne encephalitis (TBE) in the Netherlands. ( 30385073 )
2019
3
Anti-N-Methyl d-Aspartate Receptor Encephalitis and Electroconvulsive Therapy: Literature Review and Future Directions. ( 30389078 )
2019
4
Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats. ( 30396029 )
2019
5
Crustin-capped selenium nanowires against microbial pathogens and Japanese encephalitis mosquito vectors - Insights on their toxicity and internalization. ( 30466931 )
2019
6
Epidemiology of Meningitis and Encephalitis in Infants and Children in the United States, 2011-2014. ( 30531527 )
2019
7
Self-reported vaccination coverage against tick-borne encephalitis in Slovenia. ( 30197266 )
2019
8
Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia. ( 30197268 )
2019
9
Tick-borne encephalitis (TBE) in children in Europe: Epidemiology, clinical outcome and comparison of vaccination recommendations. ( 30241699 )
2019
10
Continued expansion of tick-borne pathogens: Tick-borne encephalitis virus complex and Anaplasma phagocytophilum in Denmark. ( 30245088 )
2019
11
Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China. ( 30133068 )
2019
12
Report of the 20th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE): ISW-TBE: 20 years of commitment and still challenges ahead. ( 30172555 )
2019
13
Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. ( 29588384 )
2018
14
Development of a Japanese encephalitis virus genotype V virus-like particle vaccine in silkworms. ( 29877787 )
2018
15
The intrathecal expression and pathogenetic role of Th17 cytokines and CXCR2-binding chemokines in tick-borne encephalitis. ( 29678185 )
2018
16
Mutation of I176R in the E coding region weakens Japanese encephalitis virus neurovirulence, but not its growth rate in BHK-21 cells. ( 29411136 )
2018
17
Tick-Borne Encephalitis Virus Nonstructural Protein NS5 Induces RANTES Expression Dependent on the RNA-Dependent RNA Polymerase Activity. ( 29760190 )
2018
18
Scented Sugar Baits Enhance Detection of St. Louis Encephalitis and West Nile Viruses in Mosquitoes in Suburban California. ( 29718284 )
2018
19
Development of a serodiagnostic IgM-ELISA for tick-borne encephalitis virus using subviral particles with strep-tag. ( 29960872 )
2018
20
Autoimmune GFAP astrocytopathy after viral encephalitis: A case report. ( 29499442 )
2018
21
Isolated pseudotumoural demyelination: A focal, monophasic autoimmune encephalitis? ( 29525395 )
2018
22
Predictive values and specificity of electroencephalographic findings in autoimmune encephalitis diagnosis. ( 29738958 )
2018
23
IP-10 Promotes Blood-Brain Barrier Damage by Inducing Tumor Necrosis Factor Alpha Production in Japanese Encephalitis. ( 29910805 )
2018
24
Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report. ( 29742721 )
2018
25
Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO<sup>Ar</sup>). ( 29938245 )
2018
26
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
27
Limbic Encephalitis in Association with Systemic Lupus Erythematosus. ( 29780149 )
2018
28
First detection of tick-borne encephalitis virus RNA in clinical specimens of acutely ill patients in Hungary. ( 29373305 )
2018
29
Encephalitis and transverse myelitis in dengue and chikungunya coinfection. ( 29972580 )
2018
30
Twenty years of surveillance for Eastern equine encephalitis virus in mosquitoes in New York State from 1993 to 2012. ( 29941031 )
2018
31
Human T-cell lymphotropic virus (HTLV)-associated encephalopathy: an under-recognised cause of acute encephalitis? Case series and literature review. ( 29423617 )
2018
32
Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines. ( 29325161 )
2018
33
EEG Differences in Two Clinically Similar Rapid Dementias: Voltage-Gated Potassium Channel Complex-Associated Autoimmune Encephalitis and Creutzfeldt-Jakob Disease. ( 29788790 )
2018
34
Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. ( 29540599 )
2018
35
Protecting children against Japanese encephalitis in Bali, Indonesia. ( 29976465 )
2018
36
Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017. ( 29386094 )
2018
37
Anti-Hu antibody-mediated limbic encephalitis associated with cervical cancer: A case report. ( 29607578 )
2018
38
Perfusion Imaging in Autoimmune Encephalitis. ( 29854534 )
2018
39
Controllable and uncontrollable stress differentially impact pathogenicity and survival in a mouse model of viral encephalitis. ( 29580714 )
2018
40
Limbic Encephalitis Manifesting as Selective Amnesia and Seizure-like Activity: A Case Report. ( 29397673 )
2018
41
Modelling the skip-and-resurgence of Japanese encephalitis epidemics in Hong Kong. ( 29792875 )
2018
42
Diphenyleneiodonium enhances oxidative stress and inhibits Japanese encephalitis virus induced autophagy and ER stress pathways. ( 29792860 )
2018
43
Evaluation of Argentinean Bird Species as Amplifying Hosts for St. Louis Encephalitis Virus (Flavivirus, Flaviviridae). ( 29761767 )
2018
44
Complete Genomic Characterization of Three Tick-Borne Encephalitis Viruses Detected Along the China-North Korea Border, 2011. ( 29742014 )
2018
45
Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis. ( 29259996 )
2018
46
Tick-borne encephalitis virus, Borrelia burgdorferi sensu lato, Borrelia miyamotoi, Anaplasma phagocytophilum and Candidatus Neoehrlichia mikurensis in Ixodes ricinus ticks collected from recreational islands in southern Norway. ( 29678403 )
2018
47
Why do herpes simplex encephalitis and semantic dementia show a different pattern of semantic impairment in spite of their main common involvement within the anterior temporal lobes? ( 29573378 )
2018
48
Opisthotonus (arc de cercle) in anti-NMDAR encephalitis. ( 29972427 )
2018
49
Eastern Equine Encephalitis Virus in the United States, 2003-2016. ( 29557336 )
2018
50
Status epilepticus due to acute encephalitis: NORSE does not necessarily mean worse. ( 29938873 )
2018

Variations for Encephalitis

ClinVar genetic disease variations for Encephalitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ABCD1 NM_000033.3(ABCD1): c.1866-1G> C single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 153008674: 153008674
2 ABCD1 NM_000033.3(ABCD1): c.1866-1G> C single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 153743220: 153743220

Expression for Encephalitis

Search GEO for disease gene expression data for Encephalitis.

Pathways for Encephalitis

Pathways related to Encephalitis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCL2 CCL5 CCR5 CD209 CXCL10 DDX58
2
Show member pathways
13.33 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
3
Show member pathways
13.29 CCL2 CCL5 CCR5 CXCL10 DDX58 IL1B
4
Show member pathways
12.91 CCL2 CCL5 CCR5 DDX58 IL1B IRF3
5
Show member pathways
12.83 CCL2 CCL5 CXCL10 CXCL9 IL1B IRF3
6
Show member pathways
12.8 CCL2 CCL5 CCR5 CXCL10 CXCL9
7
Show member pathways
12.53 IL1B IRF3 TICAM1 TLR3 TRAF3
8
Show member pathways
12.52 CCL5 CXCL10 DDX58 IL1B IRF3 TICAM1
9
Show member pathways
12.34 DDX58 IRF3 TICAM1 TLR3
10
Show member pathways
12.24 CCL2 CXCL10 IL1B TRAF3
11
Show member pathways
12.22 IL1B IRF3 TICAM1 TLR3
12 12.2 CXCL10 DDX58 IRF3 TRAF3
13 12.17 CCL2 CCL5 CXCL10 DDX58 IL1B IRF3
14
Show member pathways
12.16 IRF3 TICAM1 TLR3 TRAF3
15
Show member pathways
12.16 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
16
Show member pathways
12.09 CCL2 CCL5 CD209 CLEC4M CXCL10 DDX58
17 12.01 DDX58 IRF3 TICAM1 TLR3 TRAF3
18 11.95 AQP4 CCL2 CXCL10 GFAP IL1B
19
Show member pathways
11.92 CCL2 CCL5 CCR5 CXCL10 CXCL9
20 11.87 CCL2 CCL5 CXCL10 IL1B TRAF3
21 11.84 DDX58 IL1B TICAM1 TRAF3
22 11.76 CCL2 CCL5 IL1B
23 11.67 IL1B IRF3 TICAM1
24 11.65 CCL2 CCL5 CXCL10 CXCL9 IL1B
25 11.57 CCL2 CCL5 IL1B
26 11.32 CXCL10 CXCL9 IL1B
27 11.24 CCL2 CCL5 CCR5 CXCL10 IL1B
28 11.16 CCL2 CCL5 CXCL10 CXCL9 IL1B
29 10.95 CCL2 CCL5 CXCL10 CXCL9 GFAP IL1B
30 10.85 CCL2 IL1B

GO Terms for Encephalitis

Cellular components related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 AQP4 CCR5 CD209 CXCL10 CXCL9
2 host cell GO:0043657 8.96 CD209 CLEC4M

Biological processes related to Encephalitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.99 CCL5 CCR5 CXCL10 CXCL9 IL1B
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 IL1B IRF3 TICAM1 TLR3
3 response to lipopolysaccharide GO:0032496 9.97 CXCL10 IL1B IRF3 TICAM1
4 defense response GO:0006952 9.96 CCR5 CXCL10 CXCL9 TLR3
5 chemotaxis GO:0006935 9.95 CCL2 CCL5 CCR5 CXCL10 CXCL9
6 response to bacterium GO:0009617 9.92 CCL2 CXCL10 CXCL9 IRF3
7 inflammatory response GO:0006954 9.92 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
8 response to virus GO:0009615 9.91 CCL5 CXCL10 DDX58 RSAD2 TLR3
9 innate immune response GO:0045087 9.91 CD209 CLEC4M DDX58 IRF3 RSAD2 TICAM1
10 cellular response to interferon-gamma GO:0071346 9.9 AQP4 CCL2 CCL5 TLR3
11 cell chemotaxis GO:0060326 9.88 CCL2 CCL5 CCR5 CXCL10
12 viral entry into host cell GO:0046718 9.88 CD209 CLEC4G CLEC4M RPSA
13 neutrophil chemotaxis GO:0030593 9.88 CCL2 CCL5 CXCL10 CXCL9 IL1B
14 cellular response to organic cyclic compound GO:0071407 9.87 CCL2 CCL5 IL1B
15 positive regulation of T cell proliferation GO:0042102 9.87 CCL5 CD209 IL1B
16 positive regulation of interleukin-6 production GO:0032755 9.86 DDX58 IL1B TICAM1 TLR3
17 protein kinase B signaling GO:0043491 9.83 CCL2 CCL5 IL1B
18 chemokine-mediated signaling pathway GO:0070098 9.83 CCL2 CCL5 CCR5 CXCL10 CXCL9
19 toll-like receptor signaling pathway GO:0002224 9.82 TLR3 TRAF3 UNC93B1
20 positive regulation of type I interferon production GO:0032481 9.82 IRF3 TICAM1 TLR3
21 response to exogenous dsRNA GO:0043330 9.8 DDX58 IRF3 TICAM1 TLR3
22 leukocyte cell-cell adhesion GO:0007159 9.79 CCL5 CD209 CLEC4M
23 positive regulation of interleukin-8 production GO:0032757 9.79 DDX58 IL1B TLR3
24 positive regulation of interferon-beta production GO:0032728 9.78 DDX58 IRF3 TLR3
25 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.76 IRF3 TICAM1 TLR3 TRAF3
26 viral genome replication GO:0019079 9.74 CCL2 CD209 CLEC4M
27 necroptotic process GO:0070266 9.73 TICAM1 TLR3
28 positive regulation of cAMP-mediated signaling GO:0043950 9.72 CXCL10 CXCL9
29 positive regulation of monocyte chemotaxis GO:0090026 9.72 CCL5 CXCL10
30 dendritic cell chemotaxis GO:0002407 9.72 CCL5 CCR5
31 positive regulation of glial cell proliferation GO:0060252 9.72 GFAP IL1B
32 cellular response to exogenous dsRNA GO:0071360 9.72 DDX58 TLR3
33 positive regulation of T cell migration GO:2000406 9.71 CCL5 CXCL10
34 macrophage chemotaxis GO:0048246 9.71 CCL2 CCL5
35 positive regulation of interferon-alpha production GO:0032727 9.71 DDX58 IRF3
36 intracellular transport of virus GO:0075733 9.71 CD209 CLEC4M
37 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.71 TICAM1 TLR3
38 toll-like receptor 3 signaling pathway GO:0034138 9.71 TICAM1 TLR3 UNC93B1
39 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 DDX58 IL1B
40 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TICAM1 TLR3
41 positive regulation of interferon-beta biosynthetic process GO:0045359 9.69 TICAM1 TLR3
42 modulation by virus of host morphology or physiology GO:0019048 9.69 CD209 CLEC4M
43 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.68 TICAM1 TLR3
44 cell-cell recognition GO:0009988 9.68 CD209 CLEC4M
45 cellular response to dsRNA GO:0071359 9.68 IRF3 TLR3
46 negative regulation of macrophage apoptotic process GO:2000110 9.68 CCL5 CCR5
47 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.67 DDX58 TICAM1
48 detection of virus GO:0009597 9.66 DDX58 TLR3
49 virion attachment to host cell GO:0019062 9.66 CD209 CLEC4M
50 peptide antigen transport GO:0046968 9.64 CD209 CLEC4M

Molecular functions related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CCL2 CCL5 CXCL10 CXCL9 IL1B
2 virion binding GO:0046790 9.37 CD209 CLEC4M
3 CXCR3 chemokine receptor binding GO:0048248 9.32 CXCL10 CXCL9
4 chemokine activity GO:0008009 9.26 CCL2 CCL5 CXCL10 CXCL9
5 virus receptor activity GO:0001618 9.02 CCR5 CD209 CLEC4G CLEC4M RPSA
6 protein binding GO:0005515 10.21 AQP4 CCL2 CCL5 CCR5 CD209 CLEC4G

Sources for Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....